Athyrium Capital Management

Athyrium Capital Management is a specialized asset management company that invests across the broader healthcare and life sciences sectors. Founded in 2008 and headquartered in New York, the firm advises funds with more than $4.6 billion of committed capital and invests globally in both public and private companies, with a focus on commercial-stage businesses offering compelling products and differentiated services.

The firm's strategies span direct growth-equity and structured investments, including public equity, private equity, fixed income, royalties, and other structured securities. Rather than a single instrument, Athyrium deploys flexible financing solutions tailored to the growth objectives of portfolio companies and to differing company and investor mandates. Sector coverage includes biotechnology, pharmaceuticals, healthcare technology, medical devices and products, and healthcare services.

The team brings healthcare investment experience across those asset classes and works with portfolio companies as an active adviser, supported by a network of industry innovators, leaders, and experts. Structured securities and royalties financing - in which repayment is linked to product revenues rather than fixed schedules - form a distinct part of the firm's toolkit alongside conventional equity and fixed-income positions.